McGlone Suttner Wealth Management Inc. Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

McGlone Suttner Wealth Management Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,142 shares of the biopharmaceutical company’s stock after buying an additional 201 shares during the quarter. McGlone Suttner Wealth Management Inc.’s holdings in Gilead Sciences were worth $336,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. PCA Investment Advisory Services Inc. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $25,000. OFI Invest Asset Management purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $26,000. Tompkins Financial Corp increased its holdings in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Union Savings Bank purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $29,000. Finally, Fortitude Family Office LLC purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Oppenheimer dropped their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. Royal Bank of Canada decreased their target price on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Mizuho decreased their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Finally, Cantor Fitzgerald decreased their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $85.36.

Gilead Sciences Stock Performance

GILD stock traded up $0.24 during trading on Thursday, reaching $73.25. 8,369,466 shares of the company’s stock were exchanged, compared to its average volume of 7,613,002. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 1-year low of $71.37 and a 1-year high of $87.86. The company’s fifty day moving average price is $75.11 and its 200-day moving average price is $77.29. The firm has a market cap of $91.20 billion, a PE ratio of 16.40, a P/E/G ratio of 0.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter last year, the firm posted $1.67 EPS. The company’s revenue was down 3.7% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.20%. The ex-dividend date is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is currently 68.44%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now directly owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the sale, the insider now directly owns 82,729 shares in the company, valued at $7,050,992.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,242 shares of company stock valued at $1,277,726. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.